A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 5, 2011, Pages 701-706

  Avery, P J ^a   Jorgensen, A ^b   Hamberg, A K ^c   Wadelius, M ^c   Pirmohamed, M ^b   Kamali, F ^d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AGED; ARTICLE; DRUG HALF LIFE; FEMALE; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PHARMACOGENETICS; PROSPECTIVE STUDIES; THROMBOEMBOLISM; WARFARIN; YOUNG ADULT;

EID: 80054989280     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.186     Document Type: Article

References (9)

1. Kamali, F. & Wynne, H. Pharmacogenetics of warfarin. Annu. Rev. Med. 61, 63-75 (2010).
2. Jorgensen, A.L. et al. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet. Genomics 19, 800-812 (2009).
3. International Warfarin Pharmacogenetics Consortium (IWPC). Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. N. Engl. J. Med. 360, 753-764 (2009).
4. Aquilante, C.L. et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
5. D'Andrea, G. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005). (Pubitemid 40070748)
6. Sconce, E.A. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005). (Pubitemid 41510803)
7. Hamberg, A.K. et al. A pharmacometric model describing the relationship between warfarin dose and INR response taking variations in CYP2C9, VKORC1 and age into account. Clin. Pharmacol. Ther. 87, 727-734 (2010).
8. van Schie, R.M. et al. Genotype-guided dosing of coumarin derivatives: the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial design. Pharmacogenomics 10, 1687-1695 (2009).
9. Rowland, M. & Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications 87-89 (Williams & Wilkins, Baltimore, MD, 1995).